BioWorld

May 19, 2010

View Archived Issues

Forest Gets Complete Response Letter for COPD Drug Daxas

As expected by most analysts, Forest Laboratories Inc. and Nycomed GmbH Monday night received a complete response letter for their chronic obstructive pulmonary disease (COPD) drug Daxas (roflumilast). (BioWorld Today) Read More

ConjuChem Wants to Recapitalize with $35M from New Investors

Read More

Study Reports 'Smoke Sensor' Behind Emphysema's Ravages

Read More

PregLem's Esmya Positive in Phase III Uterine Fibroid Trial

Read More

Other News To Note

Read More

Stock Movers

Read More

Clinic Roundup

Read More

ATS Roundup

Read More